Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2001-11

AUTHORS

K. F. Petersen, J. T. Sullivan

ABSTRACT

AIMS/HYPOTHESIS: To study the effects of a specific glucagon receptor antagonist (Bay 27-9955), on plasma glucose concentrations and rates of glucose production in response to hyperglucagonaemia in humans. METHODS: The study was conducted as a two-dose [Low Dose Bay 27-9955 70 mg, (n = 6), High Dose Bay 27-9955 200 mg, (n = 8)], double blind, placebo controlled, crossover study. Basal glucose production was measured after an overnight fast with [6,6-2H]. At 0 min Bay 27-9955 or placebo was administered and at 120 min an infusion of somatostatin [0.1 microg x (kg x min)(-1)], insulin [24 pmol x (m2 x min)(-1)] and glucagon [3 ng x (kg x min)(-1)] was initiated. RESULTS: Basal plasma glucose concentrations were about 5 mmol/l and basal rates of glucose production were about 13 micromol x (kg x min)(-1). During the hyperglucagonaemic period, plasma glucagon concentrations doubled to 100 pg/ml, plasma glucose concentration increased by 75 % to a peak of about 10 mmol/l and glucose production doubled to about 23 micromol x (kg x min)(-1) (p < 0.0001 vs basal). In the High Dose Group these effects of glucagon were markedly blunted, plasma glucose concentrations were 7.6 +/- 1.1 mmol/l (p = 0.012 vs placebo) and rates of glucose production increased minimally to 15.3 +/- 1.9 micromol x (kg-min)(-1) (p < 0.0003 vs placebo]. In the Low Dose Group, there was a proportional decrease in the effects of Bay 27-9955 on these parameters. CONCLUSION/INTERPRETATION: Bay 27-9955 is an effective and safe glucagon antagonist in humans. Given the potentially important role of glucagon in increasing glucose production and gluconeogenesis in patients with Type II (non-insulin-dependent) diabetes mellitus this agent could represent an innovative class of therapeutic agents for the disease. More... »

PAGES

2018-2024

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s001250100006

DOI

http://dx.doi.org/10.1007/s001250100006

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021091422

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11719833


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biphenyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucagon", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycated Hemoglobin A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hormone Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kinetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Placebos", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Glucagon", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reference Values", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Somatostatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Yale University School of Medicine, Department of Internal Medicine, New Haven, Connecticut, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petersen", 
        "givenName": "K. F.", 
        "id": "sg:person.014300404317.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014300404317.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419670.d", 
          "name": [
            "Bayer Pharmaceuticals, West Haven, CT, USA, US"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sullivan", 
        "givenName": "J. T.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1172/jci109693", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002337846"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci118460", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005371133"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0026-0495(89)90129-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015417802"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197808312990901", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015987061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci115997", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017493040"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diabetes.49.12.2063", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019256166"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci108596", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022177423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000441-197008000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034050352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000441-197008000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034050352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0304-4165(73)90067-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037036142"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0304-4165(73)90067-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037036142"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci106297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040356782"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci111533", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048666084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem-48-1-171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064310374"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.17.7.415", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070731523"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.36.3.274", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070735218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.44.2.185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070737496"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2001-11", 
    "datePublishedReg": "2001-11-01", 
    "description": "AIMS/HYPOTHESIS: To study the effects of a specific glucagon receptor antagonist (Bay 27-9955), on plasma glucose concentrations and rates of glucose production in response to hyperglucagonaemia in humans.\nMETHODS: The study was conducted as a two-dose [Low Dose Bay 27-9955 70 mg, (n = 6), High Dose Bay 27-9955 200 mg, (n = 8)], double blind, placebo controlled, crossover study. Basal glucose production was measured after an overnight fast with [6,6-2H]. At 0 min Bay 27-9955 or placebo was administered and at 120 min an infusion of somatostatin [0.1 microg x (kg x min)(-1)], insulin [24 pmol x (m2 x min)(-1)] and glucagon [3 ng x (kg x min)(-1)] was initiated.\nRESULTS: Basal plasma glucose concentrations were about 5 mmol/l and basal rates of glucose production were about 13 micromol x (kg x min)(-1). During the hyperglucagonaemic period, plasma glucagon concentrations doubled to 100 pg/ml, plasma glucose concentration increased by 75 % to a peak of about 10 mmol/l and glucose production doubled to about 23 micromol x (kg x min)(-1) (p < 0.0001 vs basal). In the High Dose Group these effects of glucagon were markedly blunted, plasma glucose concentrations were 7.6 +/- 1.1 mmol/l (p = 0.012 vs placebo) and rates of glucose production increased minimally to 15.3 +/- 1.9 micromol x (kg-min)(-1) (p < 0.0003 vs placebo]. In the Low Dose Group, there was a proportional decrease in the effects of Bay 27-9955 on these parameters.\nCONCLUSION/INTERPRETATION: Bay 27-9955 is an effective and safe glucagon antagonist in humans. Given the potentially important role of glucagon in increasing glucose production and gluconeogenesis in patients with Type II (non-insulin-dependent) diabetes mellitus this agent could represent an innovative class of therapeutic agents for the disease.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s001250100006", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2423996", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2495379", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2436076", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "name": "Effects of a novel glucagon receptor antagonist (Bay 27\u20139955) on glucagon-stimulated glucose production in humans", 
    "pagination": "2018-2024", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "647d919d8b75aff2d85735a8acd01825feae66aaeada324b20cf8963febbfa8a"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11719833"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0006777"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s001250100006"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021091422"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s001250100006", 
      "https://app.dimensions.ai/details/publication/pub.1021091422"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89793_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs001250100006"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s001250100006'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s001250100006'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s001250100006'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s001250100006'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      59 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s001250100006 schema:about N10342e8f486a4a7fb0d67d520355a5fd
2 N216f14cf8c79464aa9c067182e8d31b0
3 N2aec96fe2cae486da5b193df665cff36
4 N3469c071713148898c23a720f5675518
5 N501f5f05842d460cb217302ae79f512b
6 N7abfa250fca34b9399cc23da13b7b8d9
7 N812380cfd4294a738952f27f9f4f53bd
8 N98619019b7c64f0298b0593d7eb33ec2
9 Nab6d578f36214a8b80e2909346a08df4
10 Nb107335b0d3145828c3dacb287aac3d0
11 Nca8238432e2e45d2a3b75618caf16367
12 Nd0aba40290ba430e944e722aaae4c05c
13 Nec779672d80a4b28813128cd5a414cbe
14 Nf67cc812bfc34c33b328ad18f09de81d
15 Nf71cbe0501644f1b872f6f190089a3db
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N94b44149cad141b49acc59d617e32849
19 schema:citation https://doi.org/10.1016/0026-0495(89)90129-7
20 https://doi.org/10.1016/0304-4165(73)90067-6
21 https://doi.org/10.1056/nejm197808312990901
22 https://doi.org/10.1097/00000441-197008000-00001
23 https://doi.org/10.1172/jci106297
24 https://doi.org/10.1172/jci108596
25 https://doi.org/10.1172/jci109693
26 https://doi.org/10.1172/jci111533
27 https://doi.org/10.1172/jci115997
28 https://doi.org/10.1172/jci118460
29 https://doi.org/10.1210/jcem-48-1-171
30 https://doi.org/10.2337/diab.17.7.415
31 https://doi.org/10.2337/diab.36.3.274
32 https://doi.org/10.2337/diab.44.2.185
33 https://doi.org/10.2337/diabetes.49.12.2063
34 schema:datePublished 2001-11
35 schema:datePublishedReg 2001-11-01
36 schema:description AIMS/HYPOTHESIS: To study the effects of a specific glucagon receptor antagonist (Bay 27-9955), on plasma glucose concentrations and rates of glucose production in response to hyperglucagonaemia in humans. METHODS: The study was conducted as a two-dose [Low Dose Bay 27-9955 70 mg, (n = 6), High Dose Bay 27-9955 200 mg, (n = 8)], double blind, placebo controlled, crossover study. Basal glucose production was measured after an overnight fast with [6,6-2H]. At 0 min Bay 27-9955 or placebo was administered and at 120 min an infusion of somatostatin [0.1 microg x (kg x min)(-1)], insulin [24 pmol x (m2 x min)(-1)] and glucagon [3 ng x (kg x min)(-1)] was initiated. RESULTS: Basal plasma glucose concentrations were about 5 mmol/l and basal rates of glucose production were about 13 micromol x (kg x min)(-1). During the hyperglucagonaemic period, plasma glucagon concentrations doubled to 100 pg/ml, plasma glucose concentration increased by 75 % to a peak of about 10 mmol/l and glucose production doubled to about 23 micromol x (kg x min)(-1) (p < 0.0001 vs basal). In the High Dose Group these effects of glucagon were markedly blunted, plasma glucose concentrations were 7.6 +/- 1.1 mmol/l (p = 0.012 vs placebo) and rates of glucose production increased minimally to 15.3 +/- 1.9 micromol x (kg-min)(-1) (p < 0.0003 vs placebo]. In the Low Dose Group, there was a proportional decrease in the effects of Bay 27-9955 on these parameters. CONCLUSION/INTERPRETATION: Bay 27-9955 is an effective and safe glucagon antagonist in humans. Given the potentially important role of glucagon in increasing glucose production and gluconeogenesis in patients with Type II (non-insulin-dependent) diabetes mellitus this agent could represent an innovative class of therapeutic agents for the disease.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree true
40 schema:isPartOf N165827458bc747b8a1eaa895904ad416
41 Na4ec3d232bd14e7f83db3425cbc3216a
42 sg:journal.1001482
43 schema:name Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans
44 schema:pagination 2018-2024
45 schema:productId N1b6ae4d2b253463696ad7312bd60371d
46 N1de5f58d0910452294111b3ca560a7a3
47 N7f9174b3b21448abab8051c9c57c7df7
48 Na885239102504e44b60d1caa423da553
49 Ncd08da807eb44df4a5e17404466bd2c9
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021091422
51 https://doi.org/10.1007/s001250100006
52 schema:sdDatePublished 2019-04-11T09:53
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher N12205070b9da4b7896f1a74d189ecda9
55 schema:url https://link.springer.com/10.1007%2Fs001250100006
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N10342e8f486a4a7fb0d67d520355a5fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Receptors, Glucagon
61 rdf:type schema:DefinedTerm
62 N12205070b9da4b7896f1a74d189ecda9 schema:name Springer Nature - SN SciGraph project
63 rdf:type schema:Organization
64 N165827458bc747b8a1eaa895904ad416 schema:issueNumber 11
65 rdf:type schema:PublicationIssue
66 N1b6ae4d2b253463696ad7312bd60371d schema:name doi
67 schema:value 10.1007/s001250100006
68 rdf:type schema:PropertyValue
69 N1de5f58d0910452294111b3ca560a7a3 schema:name pubmed_id
70 schema:value 11719833
71 rdf:type schema:PropertyValue
72 N1ff1532d98eb4cd2852d7a482be1bb29 schema:affiliation https://www.grid.ac/institutes/grid.419670.d
73 schema:familyName Sullivan
74 schema:givenName J. T.
75 rdf:type schema:Person
76 N216f14cf8c79464aa9c067182e8d31b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Somatostatin
78 rdf:type schema:DefinedTerm
79 N2aec96fe2cae486da5b193df665cff36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Kinetics
81 rdf:type schema:DefinedTerm
82 N3469c071713148898c23a720f5675518 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Time Factors
84 rdf:type schema:DefinedTerm
85 N501f5f05842d460cb217302ae79f512b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Hormone Antagonists
87 rdf:type schema:DefinedTerm
88 N6faa6f9b994f422485189296be27ceeb rdf:first N1ff1532d98eb4cd2852d7a482be1bb29
89 rdf:rest rdf:nil
90 N7abfa250fca34b9399cc23da13b7b8d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Placebos
92 rdf:type schema:DefinedTerm
93 N7f9174b3b21448abab8051c9c57c7df7 schema:name nlm_unique_id
94 schema:value 0006777
95 rdf:type schema:PropertyValue
96 N812380cfd4294a738952f27f9f4f53bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Male
98 rdf:type schema:DefinedTerm
99 N94b44149cad141b49acc59d617e32849 rdf:first sg:person.014300404317.81
100 rdf:rest N6faa6f9b994f422485189296be27ceeb
101 N98619019b7c64f0298b0593d7eb33ec2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Reference Values
103 rdf:type schema:DefinedTerm
104 Na4ec3d232bd14e7f83db3425cbc3216a schema:volumeNumber 44
105 rdf:type schema:PublicationVolume
106 Na885239102504e44b60d1caa423da553 schema:name readcube_id
107 schema:value 647d919d8b75aff2d85735a8acd01825feae66aaeada324b20cf8963febbfa8a
108 rdf:type schema:PropertyValue
109 Nab6d578f36214a8b80e2909346a08df4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Insulin
111 rdf:type schema:DefinedTerm
112 Nb107335b0d3145828c3dacb287aac3d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Glycated Hemoglobin A
114 rdf:type schema:DefinedTerm
115 Nca8238432e2e45d2a3b75618caf16367 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Glucagon
117 rdf:type schema:DefinedTerm
118 Ncd08da807eb44df4a5e17404466bd2c9 schema:name dimensions_id
119 schema:value pub.1021091422
120 rdf:type schema:PropertyValue
121 Nd0aba40290ba430e944e722aaae4c05c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Biphenyl Compounds
123 rdf:type schema:DefinedTerm
124 Nec779672d80a4b28813128cd5a414cbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Adult
126 rdf:type schema:DefinedTerm
127 Nf67cc812bfc34c33b328ad18f09de81d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Blood Glucose
129 rdf:type schema:DefinedTerm
130 Nf71cbe0501644f1b872f6f190089a3db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
134 schema:name Medical and Health Sciences
135 rdf:type schema:DefinedTerm
136 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
137 schema:name Clinical Sciences
138 rdf:type schema:DefinedTerm
139 sg:grant.2423996 http://pending.schema.org/fundedItem sg:pub.10.1007/s001250100006
140 rdf:type schema:MonetaryGrant
141 sg:grant.2436076 http://pending.schema.org/fundedItem sg:pub.10.1007/s001250100006
142 rdf:type schema:MonetaryGrant
143 sg:grant.2495379 http://pending.schema.org/fundedItem sg:pub.10.1007/s001250100006
144 rdf:type schema:MonetaryGrant
145 sg:journal.1001482 schema:issn 0012-186X
146 1432-0428
147 schema:name Diabetologia
148 rdf:type schema:Periodical
149 sg:person.014300404317.81 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
150 schema:familyName Petersen
151 schema:givenName K. F.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014300404317.81
153 rdf:type schema:Person
154 https://doi.org/10.1016/0026-0495(89)90129-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015417802
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/0304-4165(73)90067-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037036142
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1056/nejm197808312990901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015987061
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1097/00000441-197008000-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034050352
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1172/jci106297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040356782
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1172/jci108596 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022177423
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1172/jci109693 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002337846
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1172/jci111533 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048666084
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1172/jci115997 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017493040
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1172/jci118460 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005371133
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1210/jcem-48-1-171 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064310374
175 rdf:type schema:CreativeWork
176 https://doi.org/10.2337/diab.17.7.415 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070731523
177 rdf:type schema:CreativeWork
178 https://doi.org/10.2337/diab.36.3.274 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070735218
179 rdf:type schema:CreativeWork
180 https://doi.org/10.2337/diab.44.2.185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070737496
181 rdf:type schema:CreativeWork
182 https://doi.org/10.2337/diabetes.49.12.2063 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019256166
183 rdf:type schema:CreativeWork
184 https://www.grid.ac/institutes/grid.419670.d schema:alternateName Bayer (United States)
185 schema:name Bayer Pharmaceuticals, West Haven, CT, USA, US
186 rdf:type schema:Organization
187 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
188 schema:name Yale University School of Medicine, Department of Internal Medicine, New Haven, Connecticut, USA, US
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...